Opiant Pharmaceuticals, a specialty pharmaceutical company developing medicines for addictions and drug overdose, has halted its trial for a nasal spray designed to treat bulimia nervosa.
The California-based drugmaker announced it is discontinuing a Phase 2 clinical trial evaluating OPNT001, a naloxone nasal spray for the treatment of bulimia nervosa, after the trial failed to meet the primary endpoint of reducing the number of binging days from baseline to week 8.
Opiant's focus remains on advancing its lead product candidate, OPNT003, for treatment of opioid overdose, and other promising addiction candidates.
Read the press release
